Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 17/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 17/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18004747 | 0.84 | CHRNB2 (0.33) | KDM1AMAOB | |
| SCHEMBL18004673 | 0.84 | CYP11B1 (0.36) | — | |
| SCHEMBL16398862 | 0.83 | TRPA1 (0.34) | P2RX3P2RX2KDM1AMAOB | |
| SCHEMBL18004670 | 0.83 | TRPA1 (0.34) | P2RX3P2RX2KDM1AMAOB | |
| SCHEMBL18004748 | 0.83 | CHRNB2 (0.35) | KDM1AMAOB | |
| SCHEMBL16399147 | 0.82 | P2RX3 (0.35) | P2RX3P2RX2 | |
| SCHEMBL18004749 | 0.80 | TRPA1 (0.32) | P2RX3P2RX2KDM1AMAOB | |
| SCHEMBL18004745 | 0.80 | RET (0.35) | P2RX3P2RX2 | |
| SCHEMBL18004646 | 0.80 | FFAR4 (0.36) | — | |
| SCHEMBL18004657 | 0.80 | TRPA1 (0.34) | KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | P2RX3 4601/4885P2RX2 4531/4885EGLN2 1952/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | P2RX3 4601/4885P2RX2 4531/4885EGLN2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.